Contact Us
Drug Search Results
More Filters [+]

Oblimersen

Alternative Names: oblimersen, g3139
Latest Update: 2023-12-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency

Approved Indications: None

Known Adverse Events: None

Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oblimersen

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia

Phase 2: Squamous Cell Carcinoma|Waldenstrom Macroglobulinemia|Follicular Lymphoma|Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer|Male Breast Cancer|Mantle-Cell Lymphoma|Prostate Cancer|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|Head and Neck Cancer|Kidney Cancer|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lung Cancer|Melanoma|Neuroendocrine Carcinoma|Breast Cancer|Bladder Cancer|Carcinoma, Merkel Cell|T-Cell Cutaneous Lymphoma|Intraocular Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Plasmablastic Lymphoma|Adult T-Cell Leukemia-Lymphoma|Liver Cancer|Large-Cell Immunoblastic Lymphoma|Colorectal Cancer|Ovarian Cancer|B-Cell Marginal Zone Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Burkitt Lymphoma|Lymphomatoid Granulomatosis|Hepatocellular Carcinoma|Leukemia, Plasma Cell|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Small Cell Lung Cancer|Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumors|Renal Cell Carcinoma

Phase 1: Burkitt Lymphoma|B-Cell Marginal Zone Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Follicular Lymphoma|Mantle-Cell Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Small Cell Lung Cancer|Oncology Solid Tumor Unspecified|Melanoma|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT01200342

P2

Terminated

Melanoma

2013-09-01

0462-07-FB

P1

Terminated

Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma

2012-10-09

AGENDA

P3

Completed

Melanoma

2011-05-01

2007-003340-30

P3

Completed

Melanoma

2011-04-28

Recent News Events

Date

Type

Title

12/20/2023

PubMed

 Bcl-2 expression in cell lines breast cancer and death program.

06/13/2023

PubMed

 Metal-Organic Frameworks Facilitate Nucleic Acids for Multimode Synergistic Therapy of Breast Cancer.

02/01/2023

PubMed

 [Effect of erastin and G3139 on rat liver mitochondria in chronic alcoholic intoxication].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions